"Pipeline gave me the resources and confidence to make this major growth move - increasing our revenue, employees and plans for future growth. Pipeline's impact can't be underestimated." -Alfred Botchway

Having worked his life in the life sciences industry, Alfred combines perspectives from academia, pharmacy, biotechnology and clinical research in his role as founder and CEO of Xenometrics.

Alfred has numerous years of experience spanning academic research, a major pharmaceutical company and a contract laboratory and thereby retains a unique perspective into academic, pharmaceutical/biotechnology, and CRO activities.

His experience includes extensive research in safety pharmacology, and Alfred has monitored and conducted numerous studies on behalf of large pharmaceutical companies. Dr. Botchway has authored scholarly articles (with international circulation), and been profoundly involved with studies in support of INDs. Furthermore, he has served as a reviewer for multiple scientific manuscripts for highly esteemed international scientific journals.

In addition to membership of several international scholastic professional scientific organizations, Alfred is an active member of the Safety Pharmacology Society and currently serves on its Board of Directors as well as being the recently named Vice President Elect. Alfred is also graduate of Pipeline (an Entrepreneurial Immersion Program), and the first President of the Alumni, and currently serving as a Board member of Pipeline. Dr. Alfred Botchway is a member of the State of Kansas’ Governor’s Council of Economic Advisors.

Dr. Botchway was awarded his Ph.D. in Cardiovascular Physiology at Imperial College of Science, Technology and Medicine, University of London, UK.